Our commercially developed and validated immunoblot-based technology offers much higher sensitivity when compared to ELISA assay testing. That is why in most cases, immunoblot is typically used to confirm positive ELISA results. Due to this excellent sensitivity and specificity, immunoblot-based technology lowers false positive results and minimizes cross-reactivity. This technology is also able to distinguish between primary sensitizations, including multiple sensitizations and cross reactions. Out testing offers the capability of eliminating cross-reactivity via cross-reactivity detector markers. If said markers are positive, we re-run the test with anti-CCD antibodies for confirmation. ELISA testing does not have the capability to eliminate cross-reactivity.
Our immunoblot-based multiplex assay allows us to simultaneously determine the specific IgE to different allergen components in one test. The widely used ELISA technique is a singleplex assay.
Not only does our method allow us to run up to 100-allergen test with a single sample of 1ml serum but also to re-run the test if needed.
Our methodology also offers a 24-hour turnaround time once received at the lab. This modern immunoblot-based technique utilizes a very low amount of serum that eliminates the need for re-testing due to inadequate sample volume. The amount of information collected is maximized, using as little of your rare/precious sample as possible.
The technique produces very quick and easy-to-read and understand results identifying many IgEs within a SINGLE run.